Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Stopped early · Phase 1

Conditions studied: Gastrointestinal Stromal Tumor

In brief

RATIONALE: Imatinib mesylate and sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate given together with sunitinib in treating patients with gastrointestinal stromal tumors.

Key facts

Study ID

NCT00573404

Run by

Vanderbilt-Ingram Cancer Center

People needed

6

Starts

2007-07-01

Expected to finish

2011-03-01

Last updated by the study team

2011-11-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center at Franklin — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.